Nanoliposome with dual targeting capability, preparation method and application thereof

By designing dual-targeted nanoliposomes and using gold clusters and ferulic acid to combine targeted peptides, the problem of MRSA infection being difficult to treat in the cranial position is solved, efficient drug delivery and inflammation control are achieved, and treatment is significantly improved Effective and have preventive potential.

CN118453913BActive Publication Date: 2024-11-15THE SECOND AFFILIATED HOSPITAL TO NANCHANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410925425.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-15
Estimated Expiration
2044-07-11

AI Technical Summary

Technical Problem

MRSA infection is difficult to effectively treat in the internal cranial position. The main antibiotic vancomycin has poor ability to penetrate the blood-brain barrier, and it cannot effectively inhibit excessive activation of inflammation after removing pathogens.

Method used

Nanoliposomes with dual-targeting capabilities are designed to increase the transmittance of blood-brain barriers by water-soluble internally loaded gold clusters and fat-soluble surfaces, and combine with targeted polypeptides to achieve precise treatment.

Benefits of technology

Nanoliposomes can efficiently pass the blood-brain barrier, release drugs to kill bacteria at the infected site, reduce inflammatory response, protect glial cell function, significantly improve the therapeutic effect of MRSA infection and have preventive potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118453913B_ABST
    Figure CN118453913B_ABST
Patent Text Reader

Abstract

The present invention provides nanoliposomes with dual-targeting capabilities, a preparation method thereof and its application, and belongs to the field of biomedical technology. The water-soluble interior of the nanoliposome is loaded with gold clusters, and the fat-soluble surface is loaded with ferulic acid and combined with a targeting polypeptide. The preparation method is: the gold cluster solution is subjected to a water bath reaction to obtain an aqueous phase; phospholipids, cholesterol, ferulic acid and a targeting polypeptide solution are mixed and dissolved in anhydrous ethanol, and a fat-soluble solution is formed by a water bath reaction; the aqueous phase is stirred and the fat-soluble solution is added dropwise at a uniform speed to form a mixed liquid, and then ultrasonically oscillated in an ice bath; the supernatant is retained after low-speed centrifugation; the supernatant is discarded after high-speed centrifugation, and the remaining precipitate is a nanoliposome; it can be used to prepare a drug for treating and / or preventing intracranial MRSA infection. The product of the present invention can efficiently pass through the blood-brain barrier and be delivered to the intracranial MRSA infection site. Under the action of α-toxin, ferulic acid and gold clusters are cleaved and released to achieve the purpose of precise treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to nano liposomes with dual-targeting capabilities, a preparation method thereof and applications thereof. Background Art

[0002] Patients after intracranial surgery are more prone to lung infections, such as methicillin-resistant Staphylococcus aureus (MRSA) infection, which is prone to form biofilms, is highly pathogenic and multidrug-resistant. In addition, MRSA secretes a variety of virulence factors for invasion and colonization, including exotoxins and surface-related proteins; among them, α-toxin is one of the most important exotoxins produced by MRSA. It is a water-soluble monomer encoded by the hla gene with a molecular weight of 33.2 kDa, which can oligomerize into a 232.4 kDa membrane-penetrating heptamer. α-toxin can cause pores in the cell membrane, further exacerbating the difficulty of treating MRSA infections.

[0003] MRSA has no resistant strains to antibiotics such as vancomycin, so vancomycin is currently the main antibiotic for the treatment of MRSA infections. However, conventional antibiotics represented by vancomycin have the defect of poor blood-brain barrier (BBB) ​​permeability, resulting in weak inflammation regulation ability, and they cannot effectively inhibit excessive inflammation activation and play a cytoprotective role after clearing pathogens.

[0004] In this regard, the present invention proposes a nanoliposome with active and passive dual targeting capabilities to improve the blood-brain barrier permeability, thereby achieving the purpose of precise treatment. Summary of the invention

[0005] In view of this, the present invention aims to provide nanoliposomes with dual-targeting capabilities, a preparation method thereof and applications thereof, aiming to solve at least one technical problem among the background technologies.

[0006] The present invention is achieved in that:

[0007] The first aspect of the present invention provides a nanoliposome with dual targeting capabilities, wherein the water-soluble interior of the nanoliposome is loaded with gold clusters, and the fat-soluble surface is loaded with ferulic acid and combined with a targeting polypeptide;

[0008] The targeting polypeptide contains a peptide segment composed of alanine-histidine-leucine-aspartic acid-isoleucine-isoleucine-tryptophan-COOH.

[0009] Furthermore, the gold clusters are Au 25 (MPA) 18 , the Au 25 (MPA) 18 It refers to the use of 3-mercaptopropionic acid as the gold core Au 25 Gold clusters formed by ligands.

[0010] The first aspect of the present invention provides a method for preparing the above-mentioned nanoliposome with dual targeting capability, comprising the following steps:

[0011] The gold cluster solution is subjected to a water bath reaction to prepare an aqueous phase;

[0012] The phospholipid, cholesterol, ferulic acid and the targeting peptide solution are mixed and dissolved in anhydrous ethanol, and then placed in a constant temperature water bath for heating to form a fat-soluble solution;

[0013] Stirring the aqueous phase and uniformly adding a fat-soluble solution thereto to form a mixed liquid; then ultrasonically oscillating the mixed liquid in an ice bath;

[0014] After low-speed centrifugation, the supernatant is retained; high-speed centrifugation is performed again, and then the supernatant is discarded, and the remaining precipitate is the nanoliposome that combines the targeting polypeptide and loads ferulic acid and gold clusters. The nanoliposome has active and passive dual targeting capabilities.

[0015] Furthermore, the targeting polypeptide contains a peptide segment composed of alanine-histidine-leucine-aspartic acid-isoleucine-isoleucine-tryptophan-COOH.

[0016] Furthermore, the gold clusters are Au 25 (MPA) 18 , the Au 25 (MPA) 18 3-Mercaptopropionic acid as the gold nucleus 25 Gold clusters formed by ligands.

[0017] Furthermore, when preparing the aqueous phase, the temperature of the water bath is 35-45°C and the time is 15±2min.

[0018] Furthermore, when preparing the fat-soluble solution, the temperature of the constant temperature water bath is 35~45℃ and the time is 30±5min.

[0019] Furthermore, when the fat-soluble solution is added dropwise, the aqueous phase is stirred by magnetic stirring, and the temperature of the aqueous phase is 35-45°C.

[0020] Furthermore, the rotation speed of the low-speed centrifugation is 3000 rpm; the rotation speed of the high-speed centrifugation is 10000 rpm.

[0021] The third aspect of the present invention provides the use of the above-mentioned nanoliposome with dual-targeting capability, wherein the nanoliposome is used to prepare a drug for treating and / or preventing intracranial methicillin-resistant Staphylococcus aureus infection.

[0022] The gold clusters used in the present invention have excellent direct antibacterial activity, biofilm removal activity and NIR II region imaging potential.

[0023] Ferulic acid (3-methoxy-4-hydroxycinnamic acid) is present in high levels in traditional Chinese medicines such as Ferula, Angelica sinensis, and Ligusticum chuanxiong, and has antibacterial and anti-inflammatory properties. However, ferulic acid has poor water solubility and low bioavailability, which greatly limits its application in vivo. In the present invention, ferulic acid is loaded on liposomes, which have the advantages of adjustable size and pores, easy functionalization, high drug loading and release, high biocompatibility and safety (non-toxic, non-immunogenic), and biodegradability, and can also protect drugs in harsh environments.

[0024] The specific 5-amino acid short peptide sequence in the β-amyloid precursor protein (leucine-aspartic acid-isoleucine-isoleucine-tryptophan-COOH, RERMS) can be recognized by specific transporters / receptors in the blood-brain barrier, and then efficiently pass through the blood-brain barrier and excessively accumulate in the brain. The present invention adds histidine (H) to the RERMS short peptide to form the HRERMS polypeptide, and uses alanine as the connecting spacer, showing that HRERMS (alanine-histidine-leucine-aspartic acid-isoleucine-isoleucine-tryptophan-COOH) has a better targeting effect than RERMS.

[0025] The α-toxin secreted by MRSA infection can lead to the rapid release of intracellular water, ions and important molecules such as adenosine triphosphate (ATP), ultimately leading to cell lysis. When the nanoliposomes of the present invention enter the bacterial infection area, they can be triggered by the α-toxin to release drugs (gold clusters and ferulic acid), which can kill bacteria while reducing the inflammatory response at the infection site, promote the polarization of M1 microglia to M2 microglia, protect the mitochondrial function of glial cells, protect cells from apoptosis, and effectively improve the prognosis and survival.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] 1. The present invention designs a nanoliposome (AFAA-lipo) with active-passive dual-targeting capabilities, wherein the water-soluble interior is loaded with gold clusters, and the fat-soluble surface is loaded with ferulic acid and combined with HRERMS polypeptides; AFAA-lipo can efficiently pass through the BBB and be delivered to the intracranial MRSA infection site, and under the action of the α-toxin produced by MRSA, ferulic acid and gold clusters are cleaved and released, thereby achieving the purpose of precise treatment.

[0028] 2. The AFAA-lipo prepared by the present invention can show good therapeutic and preventive effects on intracranial MRSA infection, and thus has excellent clinical application potential in the treatment, monitoring and prevention of intracranial MRSA infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1This is the computer-simulated binding analysis of β-amyloid precursor protein and receptor for advanced glycation end products and the enlarged image of the local action domain;

[0030] Figure 2 This is a scanning electron microscope image of AFAA-lipo prepared in Example 1 of the present invention;

[0031] Figure 3 The UV-visible absorption spectra of ferulic acid, HRERMS peptide and AFAA-lipo;

[0032] Figure 4 This is a diagram showing the efficiency of the disintegration and release of ferulic acid from AFAA-lipo prepared in Example 1 of the present invention;

[0033] Figure 5 The fluorescence imaging and mean fluorescence intensity of the mouse brain 6 hours after the injection of different drugs via the tail vein are shown;

[0034] Figure 6 This is a diagram of the therapeutic effect of mice during the treatment cycle after infection;

[0035] Figure 7 This is the WB analysis of the related proteins of each gene in the cerebral cortex of each group of mice after the treatment;

[0036] Figure 8 Immunofluorescence images of macrophages RAW and microglia BV2 treated with different concentrations of ferulic acid;

[0037] Fig. 9 Optical microscopic images of bacterial biofilm and scanning electron microscopic images of bacteria after treatment in each group;

[0038] Fig.10 The permeability statistics of blood-brain barrier (BBB) ​​permeation for different concentrations of FAA-lipo and AFAA-lipo;

[0039] Fig.11 The cerebral cortex of each group of mice was subjected to H&E staining, Nissl staining analysis, and colony morphology after agar plate coating after pre-administration and MRSA infection. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific implementation cases described herein are only used to explain the present invention and are not used to limit the present invention.

[0041] The method for preparing nanoliposomes with dual targeting capabilities comprises the following steps:

[0042] S1. The gold cluster solution is subjected to a water bath reaction to obtain an aqueous phase at a water bath temperature of 35-45°C for 15±2 min.

[0043] Gold nanocluster (AuNC) is a new type of nanomaterial with fluorescent properties. The size is generally less than 2nm, with a unique electronic structure and ultra-small size, and has excellent direct antibacterial activity, biofilm removal activity and NIR II imaging potential. The gold cluster of the present invention can be any gold nanocluster allowed in the art, preferably AuNCs as the gold cluster, AuNCs refers to a nanocluster with 3-mercaptopropionic acid (MPA) as Au 25 The gold clusters formed by the ligands (Au 25 (MPA) 18 ), namely Au 25 AuNCs is a gold core, MPA is a ligand of the gold core, AuNCs has strong stability, is spherical and has good dispersibility, has a particle size of about 2nm, and has a characteristic ultraviolet absorption peak of 670nm. AuNCs can be purchased commercially or synthesized by themselves. The synthesis method can adopt a process permitted in the art, such as the conventional method using raw materials such as chloroauric acid, 3-mercaptopropionic acid, sodium hydroxide, sodium borohydride, etc., mixing and stirring a chloroauric acid solution dissolved in an organic solvent (such as methanol, ethanol, etc.) and a 3-mercaptopropionic acid solution in an ice bath, and then adding sodium borohydride and sodium hydroxide solutions to continue stirring and reacting, and then centrifuging in an ultrafiltration tube, dialysis, and freeze drying in sequence to obtain AuNCs powder. The steps, raw materials and reaction parameters of the above-mentioned synthesis method can be adjusted according to actual needs and are not specifically limited here.

[0044] S2. Mix phospholipids, cholesterol, ferulic acid and the targeting peptide solution and dissolve them in anhydrous ethanol, and then heat them in a constant temperature water bath to form a fat-soluble solution. The temperature of the water bath is 35-45°C for 30±5min.

[0045] The targeting polypeptide in the present invention is a polypeptide formed based on the β-amyloid precursor protein peptide. The short peptide of the specific 5 amino acid sequence in the β-amyloid precursor protein (Amyloid precursor protein, APP) (Leucine-Aspartic Acid-Isoleucine-Isoleucine-Tryptophan-COOH, RERMS) can be recognized by the specific transporter / receptor in the blood-brain barrier, pass through the blood-brain barrier, and excessively accumulate in the brain. Therefore, inserting the RERMS sequence on the surface of the liposome can enable it to have the function of actively targeting and passing through the blood-brain barrier; and the present invention uses the HRERMS polypeptide formed by adding histidine (H) to the RERMS short peptide, and uses alanine as the connecting spacer, showing that HRERMS (Alanine-Histidine-Leucine-Aspartic Acid-Isoleucine-Isoleucine-Tryptophan-COOH) has a better targeting effect than RERMS.

[0046] Under computer simulation, the binding status of β-amyloid precursor protein (APP) and receptor for advanced glycation end-products (RAGE) receptors was analyzed. The results are as follows: Figure 1 Advanced glycation end products are important receptors that mediate the transport of amyloid beta-peptides (Aβ) from the blood to the brain. It can be found that due to the existence of hydrogen bonds and other forces, the 328th and 752nd amino acids in APP are more tightly bound to RAGE.

[0047] S3, while stirring the aqueous phase, dropwise adding the fat-soluble solution at a uniform speed to form a mixed liquid; and then ultrasonically oscillating the mixed liquid in an ice bath;

[0048] S4, retaining the supernatant after low-speed centrifugation; performing high-speed centrifugation again, and then discarding the supernatant, and the remaining precipitate is the nanoliposome AFAA-lipo that binds the targeting polypeptide and loads ferulic acid and gold clusters, which has active and passive dual targeting capabilities;

[0049] The speed of low-speed centrifugation is about 3000 rpm and the time is about 15 minutes; the speed of high-speed centrifugation is about 10000 rpm and the time is about 15 minutes;

[0050] In a specific implementation, the weight ratio of gold clusters: phospholipids: cholesterol: ferulic acid: targeting polypeptide is 20:10~20:4~20:10~40:1; the ratio, concentration, water bath temperature and centrifugation parameters of each raw material in the present invention can be adjusted according to actual needs and are not specifically limited here.

[0051] Example 1

[0052] S1. Accurately measure 10 ml of 1 mg / ml AuNCs gold cluster solution as the aqueous phase and place it in a 40°C water bath for 15 minutes.

[0053] S2. Accurately weigh 10 mg of phospholipids, 2 mg of cholesterol, 20 mg of ferulic acid, and 0.5 ml of 1 mg / ml HRERMS peptide solution, mix and dissolve in 1 ml of anhydrous ethanol as fat-soluble raw materials; then put them in a constant temperature water bath and keep at 40°C for 30 minutes.

[0054] S3. Under the action of an electronic magnetic stirrer (temperature set at 40°C and rotation speed set at 200 rpm), the fat-soluble raw material is dripped into the aqueous phase at a uniform speed using a 1 ml syringe.

[0055] S4. Place the mixed liquid into an ice-water mixture and perform ultrasonic oscillation in an ice bath for 2 minutes.

[0056] S5. Centrifuge at 3000 rpm for 15 min, remove the precipitate and retain the supernatant; further centrifuge the supernatant at 10000 rpm for 15 min; remove the supernatant and retain the precipitate, dissolve the precipitate in ultrapure water for later use; the precipitate here is the liposome AFAA-lipo combined with the targeting peptide and loaded with ferulic acid and gold clusters.

[0057] Example 2

[0058] The AFAA-lipo prepared in Example 1 was characterized, and its efficacy and mechanism were analyzed, including:

[0059] 1. Morphological characterization

[0060] The SEM scanning electron microscope of AFAA-lipo prepared in Example 1 is as follows: Figure 2 As shown in the figure, it can be seen that AFAA-lipo is quasi-circular and has a relatively uniform particle size.

[0061] Figure 3 Figure 1 is a UV-visible absorption spectrum (UV-vis) of ferulic acid, HRERMS polypeptide and AFAA-lipo, in which a is the UV-vis of ferulic acid at different concentrations, b is the UV-vis of the HRERMS polypeptide used in Example 1 at different concentrations; and c is the UV-vis of AFAA-lipo prepared in Example 1. It can be found that AFAA-lipo has characteristic UV peaks at 240nm (HRERMS polypeptide) and 312nm (ferulic acid), proving that AFAA-lipo was successfully synthesized.

[0062] It was measured that the encapsulation efficiency of ferulic acid in AFAA-lipo was 87.89±1.56%, and the drug loading efficiency was 21.97±0.39%; the encapsulation efficiency of gold clusters was 17.76±0.52%, and the drug loading efficiency was 2.45±0.16%.

[0063] 2. Drug release rate

[0064] AFAA-lipo was placed in MRSA bacterial solution of different concentrations for treatment, and the efficiency of AFAA-lipo disintegration and release of ferulic acid was measured. The results are as follows: Figure 4 As shown, Figure 4 The horizontal axis is the concentration of MRSA bacterial solution, and the vertical axis is the release rate of ferulic acid FA; ***P<0.001, *P<0.05, **P<0.01.

[0065] It can be seen that as the MRSA content increases, the efficiency of AFAA-lipo disintegration and release of active drug FA gradually increases. The reason is that AFAA-lipo can be perforated and disintegrated by the α-toxin secreted by MRSA, thereby releasing the drug.

[0066] 3. Effect of treating MRSA infection

[0067] (1) Experimental subjects: 6-8-week-old mice were selected, n=10 / group;

[0068] (2) Experimental groups:

[0069] The NC group indicated the non-infection group;

[0070] NS group means mice were injected with normal saline after infection;

[0071] The Van group indicated that mice were injected with the drug ferulic acid FA after infection;

[0072] The FAA-lipo group indicated that mice were injected with the drug FAA-lipo after infection, and FAA-lipo refers to liposomes prepared without the addition of HRERMS peptide;

[0073] The AFAA-lipo group indicated that mice were injected with the drug AFAA-lipo after infection;

[0074] The injection concentration of the above drugs is 200 μg / mL.

[0075] (3) MRSA infection and treatment experimental process: After the mice were anesthetized with isoflurane gas, they were fixed using a stereotaxic apparatus, and the cranial puncture injection point (fontanelle position) was located. Methicillin-resistant Staphylococcus aureus (MRSA) liquid (5ul, 1.0 × 10 7 CFU mL −1), on the second day, different groups of drugs were injected into the mice through the tail vein twice a day for 3 consecutive days. At the same time, the scores of the animals after infection were evaluated, and the body weight and survival rate were monitored. Behavioral experiments and tissue section staining were used to evaluate the efficacy of each group of treatments on intracranial MRSA infection.

[0076] The animals' motor ability, food and water intake, body weight, hair condition, presence of paresis, and manifestations of epileptic seizures were examined according to the following scoring criteria: 0-healthy; 1-ruffled fur, slightly decreased mobility, and normal food and water intake; 2-ruffled fur, impaired motor ability, and reduced food and water intake; 3-ruffled fur, paresis and / or severe decrease in motor ability and / or epileptic seizures, and no food or water intake. It can be found that except for the mice in the non-infected group, the scores of mice in the remaining groups were between 2 and 3 points. At the same time, it was observed that after MRSA infection, mice showed symptoms such as reduced movement, slow reaction, body curling, and convulsions, indicating that the intracranial MRSA infection model in mice was successfully established.

[0077] (4) Analysis of experimental results

[0078] Fluorescence imaging and mean fluorescence intensity of the mouse brain 6 hours after injection of different drugs via tail vein Figure 5 As shown, in the figure a is the fluorescence imaging display, b is the quantitative analysis of the average fluorescence intensity, *P<0.05, **P<0.01; it can be seen from the figure that the fluorescence signal of AFAA-lipo in the brain is significantly higher than that of other groups, further indicating the extremely high brain targeting of AFAA-lipo in vivo.

[0079] The therapeutic effect of mice after infection during the treatment cycle is as follows Figure 6 As shown in the figure, a is the score of each group of mice during the treatment cycle, b is the weight of each group of mice during the treatment cycle, and c is the survival rate of each group of mice during the treatment cycle. The monitoring results showed that the score of the mice in the AFAA-lipo group was significantly reduced, the weight was basically stabilized at a normal level, and the final survival rate reached 70%, and its treatment effect was significantly better than that of other groups.

[0080] 4. Research on anti-inflammatory mechanism

[0081] To further clarify the specific anti-inflammatory mechanism of AFAA-lipo, WB analysis of the related proteins of each gene in the cerebral cortex of each group of mice after treatment was performed. The results are as follows Figure 7WB analysis results showed that AFAA-lipo treatment significantly inhibited the expression of TNFR1 and p-NF-κB, and there was no significant difference in the expression of NF-κB among the groups. It downregulated the expression of related pro-inflammatory factors (CD86, TNF-α, IL-6), upregulated the expression of related anti-inflammatory factors (CD206, IL-4, IL-10), and significantly reduced the expression levels of CMPK2 (upregulated after mitochondrial metabolic dysfunction) and C-MYC (upregulated after DNA damage) proteins.

[0082] In summary, AFAA-lipo exerts anti-inflammatory effects by inhibiting the TNFR1 / NF-κB inflammatory pathway and its downstream related gene transcription and expression, protecting mitochondrial function, and protecting DNA from damage.

[0083] 5. Analysis of drug action mechanism

[0084] (1) Analysis of the protective properties of one of the drug ingredients in AFAA-lipo (ferulic acid FA) on cells

[0085] Lipopolysaccharide (LPS) induced macrophages (RAW) and microglia (BV2) to construct an in vitro inflammatory response model. Under high concentration of LPS (20 μg / mL), the protective effect and specific mechanism of ferulic acid FA on cells were explored. Immunofluorescence images of RAW and BV2 cells treated with different concentrations of FA are shown in Figure 2. Figure 8 As shown; in the figure a and b are the immunofluorescence images of CD86 and CD206 in RAW cells and BV2 cells, respectively, as well as DAPI staining and fusion display images; the number in the upper right corner of the fusion corresponding figure column is the FA concentration, in µg / mL, and the scale bar = 100µm.

[0086] The results showed that as the FA concentration increased, the intracellular CD86 fluorescence signal weakened and the CD206 fluorescence signal increased; this further indicated that FA could significantly reduce the degree of cellular inflammatory response, promote the polarization of RAW and BV2 from M1 type (pro-inflammatory subtype) to M2 type (anti-inflammatory subtype), effectively implement cell protection, and this protective effect increased with the increase of FA concentration.

[0087] (2) Analysis of the antibacterial activity of the active ingredients in AFAA-lipo

[0088] The present invention investigates the antibacterial ability and mechanism of AuNCs and FA. The results show that FA alone has little inhibitory effect on MRSA bacteria. At a concentration of 10 mg / mL, its inhibition rate has not reached 60%; the antibacterial rate of AuNCs at a concentration of 200 μg / mL against MRSA exceeds 80%, and the number of bacterial colonies is relatively small; the antibacterial rate of AuNCs+FA at the same concentration is significantly improved, and FA further exerts its antibacterial effect after AuNCs destroys the bacterial cell membrane.

[0089] Fig. 9 are optical microscopic images of bacterial biofilm and scanning electron microscopic images of bacteria after treatment in each group; Fig. 9 Middle a is an optical microscope image of bacterial biofilm stained with crystal violet after treatment in different groups; it can be seen that the bacterial biofilm was almost completely removed after AuNCs+FA treatment, and the effect was significantly better than that of the other groups (control group, AuNCs group, FA group); Fig. 9 Middle (b) is the scanning electron micrograph of the bacteria under each treatment group. It can be seen that the bacteria in the control group are morphologically intact, while the bacteria are basically completely deformed and disintegrated after AuNCs+FA treatment.

[0090] 6. In vitro blood-brain barrier (BBB) ​​permeability analysis

[0091] A monolayer of bEnd.3 cells was seeded in the upper chamber of the Transwell to construct an in vitro BBB model. The BBB permeability test was performed on different concentrations of FAA-lipo and AFAA-lipo. The results are shown in Fig.10 As shown in the figure, ns means not significant. * P<0.05, ** P<0.01. It can be found that the in vitro BBB permeability of FAA-lipo and AFAA-lipo increases with the increase of concentration, and the permeability of AFAA-lipo is basically higher than that of FAA-lipo at the same concentration, which indicates that the presence of HRERMS sequence on the surface of AFAA-lipo can enable the platform to effectively target and pass through the BBB.

[0092] 7. Analysis of the effectiveness of preventing MRSA infection

[0093] The present invention investigates whether AFAA-lipo has the ability to prevent infection. Mice aged 6 to 8 weeks were selected. 30 minutes before intracranial injection of MRSA bacteria solution, different drugs were given to each group of mice in advance. One day after injection, H&E staining, Nissl staining analysis and agar plate coating were performed on the cerebral cortex of each group of mice. Fig.11 As shown, Van, FAA-lipo, and AFAA-lipo refer to the experimental groups injected with ferulic acid, FAA-lipo, and AFAA-lipo, respectively, and the NS group refers to the reference group injected with normal saline. In the figure, a is the H&E staining image of the cerebral cortex of each group of mice, b is the Nissl staining image of the cerebral cortex of each group of mice, and c is the colony morphology distribution image of the cerebral cortex of each group of mice after agar plate coating. Compared with the other groups, the number of glial cells and Nissl bodies in the cerebral cortex of the AFAA-lipo group mice under the visual field is significantly higher, and the number of colonies on the agar plate is significantly lower, indicating the effectiveness of AFAA-lipo in preventing MRSA infection.

[0094] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. Nanoliposomes with dual targeting capabilities, characterized in that: The water-soluble interior of the nanoliposome is loaded with gold clusters, and the fat-soluble surface is loaded with ferulic acid and combined with a targeting polypeptide; The targeting polypeptide contains a peptide segment composed of alanine-histidine-leucine-aspartic acid-isoleucine-isoleucine-tryptophan-COOH; The gold clusters are Au 25 (MPA) 18 , the Au 25 (MPA) 18 It refers to the use of 3-mercaptopropionic acid as the gold core Au 25 Gold clusters formed by ligands.

2. A method for preparing nanoliposomes with dual targeting capabilities, characterized in that: The preparation method is used to prepare the nanoliposome with dual-targeting ability according to claim 1, comprising the following steps: The gold cluster solution is subjected to a water bath reaction to prepare an aqueous phase; The phospholipid, cholesterol, ferulic acid and the targeting peptide solution are mixed and dissolved in anhydrous ethanol, and then placed in a constant temperature water bath for heating to form a fat-soluble solution; Stirring the aqueous phase and uniformly adding a fat-soluble solution thereto to form a mixed liquid; then ultrasonically oscillating the mixed liquid in an ice bath; After low-speed centrifugation, the supernatant is retained; high-speed centrifugation is performed again, and then the supernatant is discarded, and the remaining precipitate is the nanoliposomes that bind to the targeting polypeptide and load ferulic acid and gold clusters; The targeting polypeptide contains a peptide segment composed of alanine-histidine-leucine-aspartic acid-isoleucine-isoleucine-tryptophan-COOH.

3. The method for preparing nanoliposomes with dual targeting capabilities according to claim 2, characterized in that: The gold clusters are Au 25 (MPA) 18 , the Au 25 (MPA) 18 It refers to the use of 3-mercaptopropionic acid as the gold core Au 25 Gold clusters formed by ligands.

4. The method for preparing nanoliposomes with dual targeting capabilities according to claim 2, characterized in that: When preparing the aqueous phase, the temperature of the water bath is 35~45℃ and the time is 15±2min.

5. The method for preparing nanoliposomes with dual targeting capabilities according to claim 2, characterized in that: When preparing the fat-soluble solution, the temperature of the constant temperature water bath is 35~45℃ and the time is 30±5min.

6. The method for preparing nanoliposomes with dual targeting capabilities according to claim 2, characterized in that: When the fat-soluble solution is added dropwise, the aqueous phase is stirred by magnetic stirring, and the temperature of the aqueous phase is 35-45°C.

7. The method for preparing nanoliposomes with dual targeting capabilities according to claim 2, characterized in that: The speed of low-speed centrifugation is 3000 rpm; the speed of high-speed centrifugation is 10000 rpm.

8. Use of the nanoliposome with dual-targeting capability obtained by the preparation method according to any one of claims 2 to 7, characterized in that: The nanoliposome is used for preparing a medicine for treating and / or preventing intracranial methicillin-resistant Staphylococcus aureus infection.